C07H 19/19
With arabinosyl as the saccharide radical
Official title: with arabinosyl as the saccharide radical
C07H19/19 (With arabinosyl as the saccharide radical) appears on 24 US grants and 34 published applications in this corpus.
Search patents in C07H- Granted patents
- 24
- Published applications
- 34
- Assignees
- 26
- Inventors
- 76
- Latest grant
- 26 Aug 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 4 |
| 2008 | 1 | 0 |
| 2009 | 2 | 2 |
| 2010 | 1 | 0 |
| 2011 | 1 | 1 |
| 2012 | 1 | 6 |
| 2013 | 1 | 3 |
| 2014 | 4 | 3 |
| 2015 | 2 | 2 |
| 2016 | 2 | 3 |
| 2017 | 1 | 2 |
| 2018 | 1 | 1 |
| 2019 | 0 | 1 |
| 2020 | 1 | 1 |
| 2021 | 1 | 2 |
| 2022 | 1 | 2 |
| 2023 | 2 | 0 |
| 2024 | 0 | 1 |
| 2025 | 1 | 0 |
By publication year. Applications have been published since 2001.
Recent patents
- Therapeutic oligonucleotides26 Aug 2025US 12,398,172 B2Caris Science, Inc.
- Therapeutic oligonucleotides15 Aug 2023US 11,725,023 B2Caris Science, Inc.
- β-modified phosphoric acid compound precursor, β-modified phosphoric acid compound, reaction inhibitor and medicine containing the same, and method for inhibiting reaction7 Mar 2023US 11,597,745 B2Japan Science and Technology Agency
- Solid-state forms of Regadenoson, their use and preparation27 Dec 2022US 11,535,644 B2Macfarlan Smith Limited
- Therapeutic oligonucleotides9 Mar 2021US 10,941,176 B2Caris Science, Inc.
- Therapeutic oligonucleotides2 May 2024US 2024/0140978 A1Caris Science, Inc.
- Therapeutic oligonucleotides10 Nov 2022US 2022/0356203 A1Caris Science, Inc.
- Anti-hepatitis b virus agent3 Feb 2022US 2022/0033432 A1Daikin Industries, Ltd.
- ß-Modified Phosphoric Acid Compound Precursor, ß-Modified Phosphoric Acid Compound, Reaction Inhibitor and Medicine Containing the Same, and Method for Inhibiting Reaction16 Sep 2021US 2021/0284679 A1Japan Science and Technology Agency
- Solid-state forms of regadenoson, their use and preparation14 Jan 2021US 2021/0009626 A1Johnson Matthey Public Limited Company
Most cited
By later US patents
- Azido nucleosides and nucleotide analogs59US 8,877,731 B2Alios BioPharma, Inc. · 2014
- Nucleosides with antiviral and anticancer activity43US 8,399,428 B2Regents of the University of Minnesota · 2013
- Nucleosides with antiviral and anticancer activity25US 8,765,935 B2Regents of the University of Minnesota · 2014
- Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs18US 9,156,874 B2Nanjing Molecular Research, Inc. · 2015
- Substituted aryl piperidinylalkynyladenosines as A2AR agonists14US 7,589,076 B2PGx Health, LLC · 2009